Atypical antipsychotic multireceptor complex (MARTA)

The atypical antipsychotic multireceptor complex refers to a broad pharmacological profile involving the simultaneous modulation of several G protein-coupled receptors (Meltzer, 1991; Stahl, 2013). This profile typically includes dopamine D1, D3, and D4 receptors, various serotonin subtypes (such as 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7), alpha-1 adrenergic receptors, histamine H1 receptors, and muscarinic acetylcholine receptors (Roth et al., 2004; DrugBank, 2024). This polypharmacological approach is the hallmark of Multi-Acting Receptor-Targeted Antipsychotics (MARTAs) like clozapine and olanzapine (Stahl, 2013; PubChem, 2024). By interacting with this diverse set of targets, these medications can effectively treat the positive, negative, and cognitive symptoms of schizophrenia while minimizing the motor side effects associated with pure D2 antagonism (Meltzer, 1991; Roth et al., 2004). However, the broad activity across histamine and muscarinic systems often leads to significant side effects, including profound weight gain, sedation, and autonomic dysfunction (DrugBank, 2024; Stahl, 2013). Consequently, this target profile represents a therapeutic trade-off between high efficacy in treatment-resistant cases and a challenging safety profile related to metabolic and sedative effects (Roth et al., 2004; PubChem, 2024).

Other names

Multi-Acting Receptor-Targeted Antipsychotic profilePolypharmacological antipsychotic receptor setClozapine-like receptor profileDopamine/Serotonin/Adrenergic/Histamine/Muscarinic receptor complex

Combined antagonism of multiple dopamine, serotonin, adrenergic, histamine, and muscarinic receptors to modulate neuropsychiatric signaling pathways.